{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"A participant was considered NAb positive if baseline titer was missing or negative and participant had \\>=1 post-treatment positive titer, or positive titer at baseline and had a \\>=4-fold increase in titer from baseline in \\>=1 post-treatment sample.","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Immunogenicity analysis set included all enrolled participants who received at least one dose of study treatment and had at least one sample tested for ADA. Here, 'Overall Number of Participants Analyzed' signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From the date of first dose up to maximum of 65.1 weeks of treatment","title":"Number of Participants With Neutralizing Antibodies (NAb)","type":"SECONDARY","unitOfMeasure":"Participants"}